-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MCM-998 in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MCM-998 in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MCM-998 in Multiple Myeloma (Kahler Disease) Drug Details: MCM-998 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TL-925 in Allergic Conjunctivitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TL-925 in Allergic Conjunctivitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TL-925 in Allergic Conjunctivitis Drug Details: TL-925 is under development for...
-
Product Insights
Allergic Conjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Allergic Conjunctivitis - Drugs In Development, 2023’, provides an overview of the Allergic Conjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Conjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Conjunctivitis - Drugs In Development, 2023’, provides an overview of the Conjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Drugs In Development, 2023
Global Markets Direct’s, ‘Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Drugs In Development, 2023’, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) – Drugs In Development, 2023
Global Markets Direct’s, ‘Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) - Drugs In Development, 2023’, provides an overview of the Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) - Drugs In Development, 2023’, provides an overview of the Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Myelofibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Myelofibrosis - Drugs In Development, 2023’, provides an overview of the Myelofibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myelofibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Refractory Chronic Lymphocytic Leukemia (CLL) – Drugs In Development, 2023
Global Markets Direct’s, ‘Refractory Chronic Lymphocytic Leukemia (CLL) - Drugs In Development, 2023’, provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...